Clene Announces $4 Million Registered Direct Offering
SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing of a registered direct offering of 1,219,513 shares at a purchase price of $3.28 per share to existing shareholders, including insiders, with total gross proceeds of $4 million. The offering is expected to close on September 17, 2026.
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.